JP2002525060A - オステオプロテゲリンリガンド活性をダウンレギュレートする方法 - Google Patents

オステオプロテゲリンリガンド活性をダウンレギュレートする方法

Info

Publication number
JP2002525060A
JP2002525060A JP2000570334A JP2000570334A JP2002525060A JP 2002525060 A JP2002525060 A JP 2002525060A JP 2000570334 A JP2000570334 A JP 2000570334A JP 2000570334 A JP2000570334 A JP 2000570334A JP 2002525060 A JP2002525060 A JP 2002525060A
Authority
JP
Japan
Prior art keywords
opgl
polypeptide
nucleic acid
animal
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000570334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002525060A5 (cg-RX-API-DMAC7.html
Inventor
ホルキェ,ターベン
ハーニング,ジャスパー
Original Assignee
ファーメクサ エイ/エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーメクサ エイ/エス filed Critical ファーメクサ エイ/エス
Publication of JP2002525060A publication Critical patent/JP2002525060A/ja
Publication of JP2002525060A5 publication Critical patent/JP2002525060A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fodder In General (AREA)
JP2000570334A 1998-09-15 1999-09-13 オステオプロテゲリンリガンド活性をダウンレギュレートする方法 Pending JP2002525060A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA199801164 1998-09-15
US10289698P 1998-10-02 1998-10-02
US199801164 1998-10-02
US60/102,896 1998-10-02
PCT/DK1999/000481 WO2000015807A1 (en) 1998-09-15 1999-09-13 Method for down-regulating osteoprotegerin ligand activity

Publications (2)

Publication Number Publication Date
JP2002525060A true JP2002525060A (ja) 2002-08-13
JP2002525060A5 JP2002525060A5 (cg-RX-API-DMAC7.html) 2006-11-02

Family

ID=26065320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000570334A Pending JP2002525060A (ja) 1998-09-15 1999-09-13 オステオプロテゲリンリガンド活性をダウンレギュレートする方法

Country Status (24)

Country Link
US (2) US6645500B1 (cg-RX-API-DMAC7.html)
EP (1) EP1114166B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002525060A (cg-RX-API-DMAC7.html)
KR (1) KR100671036B1 (cg-RX-API-DMAC7.html)
CN (1) CN1318105A (cg-RX-API-DMAC7.html)
AT (1) ATE291628T1 (cg-RX-API-DMAC7.html)
AU (1) AU754971B2 (cg-RX-API-DMAC7.html)
CA (1) CA2343654A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2001789A3 (cg-RX-API-DMAC7.html)
DE (1) DE69924392T2 (cg-RX-API-DMAC7.html)
EE (1) EE200100149A (cg-RX-API-DMAC7.html)
ES (1) ES2239457T3 (cg-RX-API-DMAC7.html)
HK (1) HK1040261A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20010188A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0103578A3 (cg-RX-API-DMAC7.html)
ID (1) ID28386A (cg-RX-API-DMAC7.html)
IL (2) IL141588A0 (cg-RX-API-DMAC7.html)
NO (1) NO20011304L (cg-RX-API-DMAC7.html)
NZ (1) NZ510508A (cg-RX-API-DMAC7.html)
PL (1) PL196790B1 (cg-RX-API-DMAC7.html)
PT (1) PT1114166E (cg-RX-API-DMAC7.html)
SK (1) SK3062001A3 (cg-RX-API-DMAC7.html)
TR (1) TR200100737T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000015807A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009273466A (ja) * 2001-06-26 2009-11-26 Amgen Fremont Inc Opglへの抗体

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
HRP20010188A2 (en) * 1998-09-15 2002-04-30 Pharmexa As Method for down-regulating osteoprotegerin ligand activity
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
CA2647796A1 (en) * 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Method of inhibiting osteoclast activity
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
AU7615600A (en) * 1999-09-27 2001-04-30 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
HRP20020721B1 (en) * 2000-02-21 2012-04-30 H. Lundbeck A/S Novel method for down-regulation of amyloid
WO2001062284A2 (en) * 2000-02-21 2001-08-30 Pharmexa A/S Novel method for down-regulation of amyloid
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2001062932A1 (en) * 2000-02-23 2001-08-30 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
AU2001266604A1 (en) * 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002024228A1 (fr) * 2000-09-21 2002-03-28 Center For Advanced Science And Technology Incubation, Ltd. Méthode de régulation de la formation d'ostéoclastes
AU9303001A (en) 2000-09-22 2002-04-02 Immunex Corp Screening assays for agonists or antagonists of receptor activat or of nf-kb
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
CA2441538A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
DE60235418D1 (de) 2001-04-03 2010-04-01 Nestle Sa Osteoprotegerin in Milch
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
JP4336467B2 (ja) * 2001-10-15 2009-09-30 株式会社林原生物化学研究所 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法
EP1560843A4 (en) * 2002-01-04 2006-09-06 Xencor Inc NEW VARIANTS OF RANKL PROTEIN
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
MXPA05006147A (es) 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
KR20070058426A (ko) * 2004-06-02 2007-06-08 사이토스 바이오테크놀로지 아게 비-인간 tnf-펩티드의 담체 콘쥬게이트의 의학적 용도
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
WO2008088594A2 (en) * 2007-01-12 2008-07-24 Anaptysbio, Inc. Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species
CN101434656B (zh) * 2007-11-16 2011-12-14 首都医科大学 Opg-hsp70融合蛋白的制备方法及用途
WO2009154770A2 (en) * 2008-06-18 2009-12-23 The Texas A & M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
CN107286245B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 Pd-l1和pd-l2重组蛋白及其用途
CN107286244B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CN108498786A (zh) * 2018-02-13 2018-09-07 南昌大学第二附属医院 载骨保护素的缓释纳米粒及其制备方法和应用
KR102154637B1 (ko) * 2018-11-12 2020-09-10 조선대학교산학협력단 Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물
US20250304708A1 (en) * 2022-09-07 2025-10-02 The Regents Of The University Of California Treatment of cancer by blockade of osteoprotegerin
KR20250118303A (ko) * 2024-01-29 2025-08-06 주식회사 아크젠바이오사이온스 Rankl의 돌연변이체 및 이를 포함하는 백신 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196512A (en) * 1989-11-10 1993-03-23 Eniricerche S.P.A. Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines
JPH09505031A (ja) * 1993-08-26 1997-05-20 モーリトセン・アンド・エルスナー・エー/エス 外来t−細胞エピトープを補助として用いた、自己タンパク質に対する抗体応答の誘発

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4496393T1 (de) 1993-08-27 1996-11-21 Dow Chemical Co Verfahren zur Trennung von Enantiomeren
EP0755444A4 (en) * 1994-04-01 1998-01-14 Univ Utah MOLECULAR CLONING AND EXPRESSION OF AN INDUCTIBLE PROTEASOME ACTIVATOR BY INTERFERON GAMMA
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
PT1114864E (pt) * 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
ATE497001T1 (de) * 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
HRP20010188A2 (en) * 1998-09-15 2002-04-30 Pharmexa As Method for down-regulating osteoprotegerin ligand activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196512A (en) * 1989-11-10 1993-03-23 Eniricerche S.P.A. Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines
JPH09505031A (ja) * 1993-08-26 1997-05-20 モーリトセン・アンド・エルスナー・エー/エス 外来t−細胞エピトープを補助として用いた、自己タンパク質に対する抗体応答の誘発

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN6009055699, Biochemical and Biophysical Research Communication, 199805, Vol.246,No.2, p337−341 *
JPN6009055701, Biochemical and Biophysical Research Communication, 199805, Vol.246,No.1, p199−204 *
JPN6009055702, Proc.Natl.Acad.Sci.USA, 199803, Vol.95,No.7, p3597−3602 *
JPN6009055703, Cell, 199804, Vol.93,No.2, p165−176 *
JPN6009055704, Biochemical and Biophysical Research Communication, 199806, Vol.247,No.3, p610−615 *
JPN6009055705, Annals of Oncology, 199804, Vol.9,No.4, p431−435 *
JPN6009055706, Human Reproduction Update, 1997, Vol.3,No.4, p301−310 *
JPN6009055708, Journal of Immunology, 1992, Vol.149,No.2, p717−721 *
JPN6009055710, Journal of Immunology, 1994, Vol.152,No.6, p2921−2929 *
JPN6009055712, European Journal of Immunology, 1989, Vol.19,No.12, p2237−2242 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009273466A (ja) * 2001-06-26 2009-11-26 Amgen Fremont Inc Opglへの抗体
JP2012153701A (ja) * 2001-06-26 2012-08-16 Amgen Fremont Inc Opglへの抗体
JP2012229236A (ja) * 2001-06-26 2012-11-22 Amgen Fremont Inc Opglへの抗体

Also Published As

Publication number Publication date
EE200100149A (et) 2002-08-15
NO20011304D0 (no) 2001-03-14
IL141588A (en) 2008-07-08
CN1318105A (zh) 2001-10-17
IL141588A0 (en) 2002-03-10
TR200100737T2 (tr) 2001-07-23
PT1114166E (pt) 2005-08-31
AU754971B2 (en) 2002-11-28
HRP20010188A2 (en) 2002-04-30
DE69924392D1 (de) 2005-04-28
DE69924392T2 (de) 2006-03-09
WO2000015807A1 (en) 2000-03-23
SK3062001A3 (en) 2002-02-05
EP1114166A1 (en) 2001-07-11
KR20010085807A (ko) 2001-09-07
CA2343654A1 (en) 2000-03-23
AU5617399A (en) 2000-04-03
KR100671036B1 (ko) 2007-01-18
PL346698A1 (en) 2002-02-25
HUP0103578A3 (en) 2005-11-28
CZ2001789A3 (cs) 2001-08-15
US20040115199A1 (en) 2004-06-17
ID28386A (id) 2001-05-17
EP1114166B1 (en) 2005-03-23
ATE291628T1 (de) 2005-04-15
HK1040261A1 (zh) 2002-05-31
NO20011304L (no) 2001-05-15
US6645500B1 (en) 2003-11-11
HUP0103578A2 (hu) 2002-01-28
ES2239457T3 (es) 2005-09-16
PL196790B1 (pl) 2008-01-31
NZ510508A (en) 2005-05-27

Similar Documents

Publication Publication Date Title
EP1114166B1 (en) Method for down-regulating osteoprotegerin ligand activity
US7070784B1 (en) Method for down-regulating GDF-8 activity using immunogenic GDF-8 analogues
AU2006312847A1 (en) Therapeutic vaccines targeting HMGB1
US20070184023A1 (en) Method for down-regulation of vegf
US20020172673A1 (en) Method for down-regulating IgE
JP2005518194A (ja) 乱交雑t細胞エピトープ挿入物を有するマルチマータンパク質の免疫原性擬態物
US20080253993A1 (en) Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope
WO2009003889A2 (en) Immunogenic analogues of rankl
RS49960B (sr) Postupak za regulisanje smanjenja aktivnosti osteoprotegerinskog liganda
JP2007523605A (ja) 細胞毒性が低減された免疫原性ヒトTNFαアナログおよびそれらの製造方法
EP1541587A2 (en) Method for down-regulating osteoprotegerin ligand activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100622